Jamshedpur Reporter

Delveinsight Business Research LLP

The Marginal Zone Lymphoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Marginal Zone Lymphoma: An Overview

Marginal zone B-cell lymphoma or Marginal Zone Lymphoma (MZL) is a group of indolent (slow-growing) NHL B-cell lymphomas, which account for approximately 5‒17% of all NHL cases. Marginal Zone Lymphoma consists of three different subtypes with extranodal being the most commonly reported, representing 50‒70% of MZL, followed by splenic (20%) and nodal (10%).

Currently, the first-line management of Marginal Zone Lymphoma totally depends on supportive therapies, and the two therapies that are approved are for relapsed and refractory MZL patient pool. Additionally, all the emerging therapies that are expected to launch in the forecasted period are also focusing on the relapsed and refractory MZL pool.

Marginal Zone Lymphoma Market Key Facts

• The total incident population of Non-Hodgkin lymphoma (NHL) in the 7MM was estimated to be 166,900+ in 2017. Out of these the total incident population of Marginal Zone Lymphoma in the 7MM in 2017 was observed to be 21,200+.

• In 2017, a higher number of males were affected by Marginal Zone Lymphoma, i.e., 54% of the total incident Marginal Zone Lymphoma population in the United States, which is equivalent to 3,800+ cases. In comparison to this, for females, the number of cases observed was 3,300+ in 2017.

• Among the EU5 countries, the UK had the highest incident population of Marginal Zone Lymphoma with 3,140+ cases, followed by France which had an incident population of 1,740+ in 2017.

• The United States showed the highest incident cases of Marginal Zone Lymphoma, as compared to EU5, and Japan. As per the estimates, the US accounts for approximately 33.9% of total cases, for MZL, in the 7MM countries.

Marginal Zone Lymphoma Market

Marginal Zone Lymphoma market size in the 7MM was found to be USD 427.16 Million in 2017. Marginal Zone Lymphoma market size is expected to increase during the forecast period owing to the increasing incident population in the 7MM and the launch of upcoming therapies during the forecast period.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Marginal Zone Lymphoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Marginal Zone Lymphoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Marginal Zone Lymphoma Epidemiology

The epidemiology section covers insights into the historical and current Marginal Zone Lymphoma patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Marginal Zone Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Marginal Zone Lymphoma market or expected to get launched in the market during the study period. The analysis covers Marginal Zone Lymphoma market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Marginal Zone Lymphoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market

Marginal Zone Lymphoma Therapeutics Analysis

Several pharmaceutical key players have taken the initiative to meet the unmet needs of the present situation of the Marginal Zone Lymphoma market. Some of the key players are in the late and mid clinical development stages with their leading drug candidates. The launch of emerging products during the forecast period will fuel the Marginal Zone Lymphoma market growth.

Some of the key companies in the Marginal Zone Lymphoma Market include:

• AbbVie

• ArQule

• AstraZeneca

• Bayer

• BeiGene

• Bristol-Myers Squibb

• Celgene Corporation

• Cellectar Biosciences

• Eli Lilly

• Gilead Sciences

• InnoCare Pharma

• Innovent Biologics

• Janssen Biotech

• Loxo Oncology

• MEI Pharma

• Merck

• NantKwest/ImmunityBio

• Nordic Nanovector

• Roche Pharma

• TG Therapeutics

• TriSalus Life Sciences

• Verastem/Secura Bio

And many others

Marginal Zone Lymphoma Therapies covered in the report include:

• Revlimid (lenalidomide) in combination with rituximab

• Imbruvica (ibrutinib)

• Umbralisib (TGR-1202)

• Aliqopa (Copanlisib)

• Ublituximab

• Obinutuzumab

• Yescarta (axicabtagene ciloleucel)

• Keytruda (Pembrolizumab)

• CLR 131

• Parsaclisib

• Nivolumab (Oppdivo)

• Calquence (acalabrutinib)

• Betalutin (177Lu-satetraxetan-lilotomab) 

• Navitoclax (ABT-263)

• Orelabrutinib (ICP-022)

• M7583

• ARQ 531

• Duvelisib

• Zanubrutinib

• Zandelisib

• ALT-803

• LOXO-305

• SD-101

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies-   https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Marginal Zone Lymphoma Competitive Intelligence Analysis

4. Marginal Zone Lymphoma Market Overview at a Glance

5. Marginal Zone Lymphoma Disease Background and Overview

6. Marginal Zone Lymphoma Patient Journey

7. Marginal Zone Lymphoma Epidemiology and Patient Population

8. Marginal Zone Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Marginal Zone Lymphoma Unmet Needs

10. Key Endpoints of Marginal Zone Lymphoma Treatment

11. Marginal Zone Lymphoma Marketed Products

12. Marginal Zone Lymphoma Emerging Therapies

13. Marginal Zone Lymphoma Seven Major Market Analysis

14. Attribute Analysis

15. Marginal Zone Lymphoma Market Outlook (7 major markets)

16. Marginal Zone Lymphoma Access and Reimbursement Overview

17. KOL Views on the Marginal Zone Lymphoma Market.

18. Marginal Zone Lymphoma Market Drivers

19. Marginal Zone Lymphoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Latest Reports By DelveInsight

Follicular Lymphoma Market

DelveInsight’s “Follicular Lymphoma Market” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). The Follicular Lymphoma Market is expected to grow immensely in the coming years owing to the active participation of key companies such as Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, BeiGene, and others.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/